An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Guan Zhongzhen, MD
Principal Investigator
SYS Cancer Center
China: Food and Drug Administration
D4200L00004
NCT00503711
September 2006
November 2007
Name | Location |
---|